Bayer SG&A Expenses 2010-2024 | BAYRY

Bayer sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Bayer Annual SG&A Expenses
(Millions of US $)
2023 $16,164
2022 $17,829
2021 $18,131
2020 $18,199
2019 $18,104
2018 $18,281
2017 $14,854
2016 $16,300
2015 $16,062
2014 $16,961
2013 $15,890
2012 $15,244
2011 $17,175
2010 $17,151
2009 $15,624
Bayer Quarterly SG&A Expenses
(Millions of US $)
2024-06-30 $3,968
2024-03-31 $4,156
2023-12-31 $3,874
2023-09-30 $3,923
2023-06-30 $4,018
2023-03-31 $4,349
2022-12-31 $4,534
2022-09-30 $4,108
2022-06-30 $4,759
2022-03-31 $4,427
2021-12-31 $4,930
2021-09-30 $4,441
2021-06-30 $4,515
2021-03-31 $4,245
2020-12-31 $4,158
2020-09-30 $5,761
2020-06-30 $4,048
2020-03-31 $4,233
2019-12-31 $4,088
2019-09-30 $4,241
2019-06-30 $4,998
2019-03-31 $4,776
2018-12-31 $6,030
2018-09-30 $4,452
2018-06-30 $4,190
2018-03-31 $3,609
2017-12-31 $3,528
2017-09-30 $3,560
2017-06-30 $4,161
2017-03-31 $3,605
2016-12-31 $4,537
2016-09-30 $3,955
2016-06-30 $4,045
2016-03-31 $3,763
2015-12-31 $4,179
2015-09-30 $3,823
2015-06-30 $4,123
2015-03-31 $3,937
2014-12-31 $4,762
2014-09-30 $4,059
2014-06-30 $4,220
2014-03-31 $3,920
2013-12-31 $4,009
2013-09-30 $3,964
2013-06-30 $4,085
2013-03-31 $3,833
2012-12-31 $4,128
2012-09-30 $3,689
2012-06-30 $3,831
2012-03-31 $3,596
2011-12-31 $4,524
2011-09-30 $3,814
2011-06-30 $4,259
2011-03-31 $4,577
2010-12-31 $5,386
2010-09-30 $4,264
2010-06-30 $4,001
2010-03-31 $3,500
2009-12-31 $4,414
2009-09-30 $3,783
2009-06-30 $4,009
2009-03-31 $3,418
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94